Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2020

View Archived Issues

First participant dosed in phase I study of SRN-14/GL2-800, a novel nucleic acid drug

Octapharma launches phase III superiority study of Panzyga in PANS

"Energy blueprint" maps how cells make, use ATP

C3AR1 as a novel biomarker for biliary atresia and primary sclerosing cholangitis

PPEF2 identified as potential new prognostic biomarker in HCC

S-62798 demonstrates efficacy in mouse model of thromboembolism

Palobiofarma reports promising phase II data on PBF-680 for asthma

MOSPD2 found as a therapeutic target for treating NASH

FDA grants accelerated approval to Gavreto for metastatic RET fusion-positive NSCLC

Purdue University compounds are active against vancomycin-resistant enterococcus

Denali Therapeutics identifies new EIF2B activators

New betulin acid derivatives discovered at Hetero Labs

Bristol-Myers Squibb discovers farnesoid X receptor agonists

New FGFR-4 inhibitors presented by BridGene Biosciences

Midwestern University describes isotopically stabilized tetronimide compounds

New severe aortic valve calcification and stenosis rabbit model developed

Northwestern University designs spherical nucleic acid triple-negative breast cancer vaccines

FluoGuide obtains Danish clearance for phase I/II trial of FG-001 to guide glioma surgery

Twist reports data on IgG antibodies and VHH nanobodies against SARS-CoV-2

Australian funding to support Pharmaxis' development of PXS-4699 for Duchenne muscular dystrophy

Akston signs up CRO to support phase I testing of COVID-19 vaccine candidate AKS-452

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...